Trial Profile
A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Paediatric Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Fibrin (Primary) ; Fibrin (Primary) ; Oxidised cellulose
- Indications Surgical blood loss
- Focus Therapeutic Use
- Sponsors Ethicon
- 07 Sep 2022 Status changed from recruiting to completed.
- 14 Jan 2022 This trial has been completed in Belgium (End Date: 12 Nov 2021), according to European Clinical Trials Database record.
- 13 Aug 2021 Planned End Date changed from 31 Jul 2021 to 1 Jul 2022.